[
  {
    "ts": null,
    "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=d3a31cbdac067ca49e6e6387abe0bdbf7752ac46d99374295e3dbe10be2a46a9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741019460,
      "headline": "AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "id": 132977455,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=d3a31cbdac067ca49e6e6387abe0bdbf7752ac46d99374295e3dbe10be2a46a9"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Ghost Of Stagflation Alarms Investors",
    "summary": "The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board following the weekend surge in crypto.",
    "url": "https://finnhub.io/api/news?id=0f2ff858b9d36ccef7c905b89ca723267377cf787a012acd0bd3ede993ae83af",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741009860,
      "headline": "Wall Street Lunch: Ghost Of Stagflation Alarms Investors",
      "id": 132955746,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/171293890/image_171293890.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "The stagflation specter is spooking traders today, wiping out the risk-on move that was buoying stocks and weighing on board following the weekend surge in crypto.",
      "url": "https://finnhub.io/api/news?id=0f2ff858b9d36ccef7c905b89ca723267377cf787a012acd0bd3ede993ae83af"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.",
    "summary": "AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.",
    "url": "https://finnhub.io/api/news?id=c53eabc83275f6b74bc6e2f8fe76d85153fa1ace0d38e7acdda5289836b500e4",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740996273,
      "headline": "AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.",
      "id": 132956087,
      "image": "",
      "related": "ABBV",
      "source": "DowJones",
      "summary": "AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.",
      "url": "https://finnhub.io/api/news?id=c53eabc83275f6b74bc6e2f8fe76d85153fa1ace0d38e7acdda5289836b500e4"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion",
    "summary": "By Colin Kellaher AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and...",
    "url": "https://finnhub.io/api/news?id=4a9cf75e607ec1f443d2bd360952f7b7db851244d8f660b29bac90421ee95ba9",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740985147,
      "headline": "AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion",
      "id": 132952665,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "By Colin Kellaher AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and...",
      "url": "https://finnhub.io/api/news?id=4a9cf75e607ec1f443d2bd360952f7b7db851244d8f660b29bac90421ee95ba9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity",
    "summary": "Partnership marks AbbVie's entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure...",
    "url": "https://finnhub.io/api/news?id=acade03637a275dd9454894d991d83db8df3a9985ddaaef28484c30ed2803cfe",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1740964324,
      "headline": "AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity",
      "id": 132947343,
      "image": "",
      "related": "ABBV",
      "source": "Finnhub",
      "summary": "Partnership marks AbbVie's entrance into the obesity fieldAgreement will enable the incorporation of GUB014295, an amylin peptide discovered and developed by Gubra, into AbbVie's global infrastructure...",
      "url": "https://finnhub.io/api/news?id=acade03637a275dd9454894d991d83db8df3a9985ddaaef28484c30ed2803cfe"
    }
  }
]